Analytical Data
-
Gene name
BMP2
- Application
-
Alternative Names
BMP2；BMP2A；Bone morphogenetic Protein 2
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P12643
-
Expression Region
283-396aa
-
AA Sequence
MQAKHKQRKR LKSSCKRHPL YVDFSDVGWN DWIVAPPGYH AFYCHGECPF PLADHLNSTN HAIVQTLVNS VNSKIPKACC VPTELSAISM LYLDENEKVV LKNYQDMVVE GCGCR
-
Molecular Weight
13 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Bone morphogenetic protein-2 (BMP2) is a crucial member of the transforming growth factor-beta (TGF-β) superfamily, known for its pivotal role in osteogenesis and bone regeneration. Initially identified for its ability to induce bone formation, BMP2 has garnered significant attention in the fields of tissue engineering and regenerative medicine. Researchers have explored the recombinant expression of BMP2 to develop therapeutic applications, particularly for bone defects and fractures that fail to heal properly. The recombinant protein is typically produced in various expression systems, allowing for the generation of bioactive BMP2 at scale. Studies have demonstrated that BMP2 can promote the proliferation and differentiation of osteoblasts, the cells responsible for bone formation, thereby enhancing the healing process in bone-related injuries. Furthermore, BMP2's signaling pathway has been implicated in various physiological processes, including embryonic development and tissue homeostasis. Given its multifaceted roles, understanding BMP2’s mechanisms of action and improving its delivery and effectiveness remain critical focal points in the ongoing research. Advances in biomaterial technology, gene therapy, and controlled-release systems have the potential to optimize BMP2 applications, making it a promising candidate for clinical therapies aimed at addressing bone-related conditions. Overall, the study of BMP2 recombinant protein continues to be a vibrant area of research with significant implications for enhancing bone repair strategies in the medical field.
